Xencor (NASDAQ:XNCR) Announces Earnings Results

Xencor (NASDAQ:XNCR) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.51, Zacks reports. The business had revenue of $51.22 million for the quarter, compared to analyst estimates of $18.89 million. Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The business’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.41) EPS.

Xencor Price Performance

NASDAQ XNCR traded up $0.09 on Thursday, hitting $19.93. The company had a trading volume of 599,762 shares, compared to its average volume of 840,509. The company has a market capitalization of $1.48 billion, a PE ratio of -8.66 and a beta of 0.85. The company’s fifty day moving average price is $15.35 and its 200-day moving average price is $13.27. Xencor has a 12-month low of $6.92 and a 12-month high of $21.96.

Hedge Funds Weigh In On Xencor

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. increased its stake in shares of Xencor by 5.7% during the fourth quarter. Invesco Ltd. now owns 265,820 shares of the biopharmaceutical company’s stock worth $4,070,000 after purchasing an additional 14,216 shares in the last quarter. EP Wealth Advisors LLC acquired a new position in shares of Xencor during the 4th quarter worth about $202,000. XTX Topco Ltd purchased a new position in Xencor in the 4th quarter valued at about $490,000. Voloridge Investment Management LLC purchased a new position in Xencor in the 4th quarter valued at about $1,343,000. Finally, Virtus Investment Advisers LLC lifted its stake in Xencor by 33.5% in the 4th quarter. Virtus Investment Advisers LLC now owns 16,103 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 4,037 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a report on Wednesday, June 24th. Royal Bank Of Canada increased their price target on shares of Xencor from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Thursday. Wedbush raised their price target on shares of Xencor from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday. Wall Street Zen cut shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Zacks Research raised shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and an average target price of $25.12.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.